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Abstract
Background: High throughput single-cell RNA sequencing (scRNA-Seq) has emerged as a powerful tool for exploring
cellular heterogeneity among complex human cancers. scRNA-Seq studies using fresh human surgical tissue are
logistically difficult, preclude histopathological triage of samples, and limit the ability to perform batch processing. This
hindrance can often introduce technical biases when integrating patient datasets and increase experimental costs.
Although tissue preservation methods have been previously explored to address such issues, it is yet to be examined
on complex human tissues, such as solid cancers and on high throughput scRNA-Seq platforms.
Methods: Using the Chromium 10X platform, we sequenced a total of ~ 120,000 cells from fresh and cryopreserved
replicates across three primary breast cancers, two primary prostate cancers and a cutaneous melanoma. We
performed detailed analyses between cells from each condition to assess the effects of cryopreservation on cellular
heterogeneity, cell quality, clustering and the identification of gene ontologies. In addition, we performed single-cell
immunophenotyping using CITE-Seq on a single breast cancer sample cryopreserved as solid tissue fragments.
Results: Tumour heterogeneity identified from fresh tissues was largely conserved in cryopreserved replicates. We
show that sequencing of single cells prepared from cryopreserved tissue fragments or from cryopreserved cell
suspensions is comparable to sequenced cells prepared from fresh tissue, with cryopreserved cell suspensions
displaying higher correlations with fresh tissue in gene expression. We showed that cryopreservation had minimal
impacts on the results of downstream analyses such as biological pathway enrichment. For some tumours,
cryopreservation modestly increased cell stress signatures compared to freshly analysed tissue. Further, we
demonstrate the advantage of cryopreserving whole-cells for detecting cell-surface proteins using CITE-Seq, which is
impossible using other preservation methods such as single nuclei-sequencing.
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Conclusions: We show that the viable cryopreservation of human cancers provides high-quality single-cells for multi-
omics analysis. Our study guides new experimental designs for tissue biobanking for future clinical single-cell RNA
sequencing studies.
Keywords: Single-cell RNA sequencing, Cryopreservation, Tumour heterogeneity, CITE-Seq, Breast cancer, Prostate
cancer, Melanoma
Background
The tumour microenvironment (TME) is composed of
neoplastic cells, mesenchymal and immune cells that
interact to shape cancer progression and therapeutic
response [1]. Advances in high-throughput single-cell
RNA sequencing (scRNA-seq) technologies have rapidly
developed in recent years, providing a powerful platform
to resolve the aetiology of the TME in solid cancers [2].
Performing scRNA-seq on clinical samples remains
logistically and technically challenging, mainly due to
the transport of patient tissue from operation rooms to
laboratories for processing, which are often complicated
by short notices and core-facility access hours. The need
to process fresh tissue specimens at the time of tissue
availability, often as a single specimen, often introduces
large experimental costs and confounding batch effects
upon studies with large numbers of patients and pre-
vents the selection and triage of cases for analysis based
on histopathological analysis.
Several approaches have been developed to address
such issues. Madissoon et al. benchmarked short-term
cold preservation of tissue prior to scRNA-Seq, which
showed little impact on transcriptome integrity within
the first 24 h [3]. Cell type-specific transcriptional
changes can emerge after longer cold preservation pe-
riods (> 24 h), particularly affecting immune subpopula-
tions in normal tissues [3]. Cold preservation is yet to be
evaluated for complex tissues such as solid tumours,
which possess distinct features in tissue viability. Factors
including tissue necrosis, hypoxia and therapeutic treat-
ments often result in poor viability of cells in solid
tumour tissues. Regardless, such short-term storage
periods still limit the ability to perform simultaneous
sample processing. In particular for microfluidic droplet-
based scRNA-Seq, this can result in batch effects for lar-
ger studies processed over several time points [4], where
cell fixation and cryopreservation methods can minimise
such issues. Cell fixation methods using agents such as
methanol [5] or dithio-bis (succinimidyl propionate)
(DSP) [6] are effective and can be applied to overcome
several barriers of cold preservation. However, scRNA-
Seq studies have shown that fixation methods can
elevate ambient background RNA and do not maintain
cell integrity as effectively as cryopreservation using
DMSO [7]. Furthermore, fixation methods are not always
practical with solid cancers which require lengthy dissoci-
ation protocols and also preclude certain downstream
procedures such as antibody staining or cell culture.
Although sequencing of nuclei from snap frozen tissue
can be applied to avoid dissociation methods [8], this ap-
proach is not compatible with powerful cell surface immu-
nophenotyping methods with DNA-barcoded antibodies
such as CITE-Seq [9]. Sequencing of nuclei also does not
permit the selection of cell subsets of interest or the
removal of low-quality cells prior to capture.
While cryopreservation of cells using DMSO has been
applied to study cell lines, PBMCs and other model
organisms by scRNA-Seq [7, 10, 11], it is unclear how
more complex solid tissues may be impacted by this
freezing process. An important study by Guillaumet-
Adkins et al. showed that the cryopreservation of whole-
cells and tissues can be used to conserve transcriptional
profiles from experimental systems such as human cell
lines and mouse tissues [12]. These models represent
fairly homogeneous systems, and it is unclear whether
the highly heterogeneous nature of the TME is also
conserved following cryopreservation. In addition, stud-
ies have only benchmarked cryopreservation of intact
tissues using low-throughput plate-based scRNA-seq
technology [12, 13], where highly viable cells are selected
by FACS for immediate lysis and mRNA hybridisation
[14]. It is yet to be determined if cryopreservation of tis-
sues can be applied to more recent high throughput
scRNA-Seq platforms such as the Chromium 10X
platform. These platforms are fundamentally different to
FACS-based scRNA-Seq methods, as single-cells are
captured through droplet-based microfluidics, where via-
bility selection is not simultaneously performed. More
recent studies using droplet-based microfluidics have
analysed circulating T-regulatory cells [15] and have
shown that heat shock and cell stress pathways can
emerge as transcriptional artefacts from cryopreserva-
tion. It is unclear how these stress responses affect the
diversity of cell types within intact tissues, where the
efficiency of the cryoprotectant may be affected, and
further require tissue dissociation.
In this study, we aimed to examine the effect of
cryopreserving dissociated cells and solid tissue frag-
ments from human tumours prior to scRNA-Seq on the
10X Chromium platform. We tested this across three
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common cancer types: breast, prostate and melanoma.
Following cryopreservation, we demonstrated a strong
conservation of the heterogeneous neoplastic, mesenchy-
mal and immune subpopulations. We show that scRNA-
Seq results of cells from cryopreserved solid tissue and
from cryopreserved dissociated cell suspensions are com-
parable to those from cells prepared from fresh tissue,
with minimal impact on downstream analysis methods. In
some tumours sequenced from cryopreserved solid tissues
and after overnight cold storage conditions, we observe
some minor gene expression changes associated with cell
stress responses. Lastly, we show that cryopreserving
whole-cells allows for powerful immunophenotyping
methods such as CITE-Seq, which is not possible using
nuclei-based sequencing methods. Our findings allow a
simple biobanking protocol to process patient samples,
significantly decreasing technical variation among larger
patient cohorts and serial time-points analyses. Our
biobanking protocol unlocks patient cohorts previously
collected in such a manner and serves as a guide for the
sample collection in future clinical scRNA-Seq studies.
Methods
Primary tissue dissociation and sample preparation
We examined tissue from three primary breast cancers,
two primary prostate cancers and a lymph node metastasis
from a patient with a cutaneous melanoma (Additional file
1). Fresh surgically resected tissues were washed with RPMI
1640 (ThermoFisher Scientific) and diced into 1–2mm3
pieces. Tissue pieces were mixed and approximately one
third were viably frozen in cryogenic vials in 5% dimethyl
sulfoxide (DMSO) and 95% fetal bovine serum (FBS) at
1 °C/minute in −80 °C using Mr. Frosty™ Freezing
Containers (ThermoFisher). This was classified as the solid
cryopreserved tissue (CT) sample. The remaining tissue
was further minced with scissors and enzymatically dissoci-
ated using the Human Tumour Dissociation Kit (Miltenyi
Biotec) following the manufacturer’s protocol. Following in-
cubation with the enzymes, the sample was resuspended in
media (80% RPMI 1640, 20% FBS) and filtered through
MACS® SmartStrainers (70 μM; Miltenyi Biotec). The
resulting single cell suspension was centrifuged at 300×g
for 5min. At this stage, a proportion of the dissociated cell
suspension was frozen in cryogenic vials in 10% DMSO,
50% FBS, and 40% RPMI 1640 at 1 °C/minute in −80 °C
using Mr. Frosty™ Freezing Containers (ThermoFisher).
This was classified as the dissociated cryopreserved cell sus-
pension (CCS) sample. For the dissociated fresh tissue (FT)
sample, red blood cells were lysed with Lysing Buffer (Bec-
ton Dickinson) for 5min and neutralised with media (80%
RPMI 1640, 20% FBS). Cells were further filtered through a
40-μm filter and centrifuged at 300×g for 5min. Viability
was assessed using Trypan Blue (ThermoFisher). For
samples with a viability score of < 80%, enrichment was
performed using the EasySep Dead Cell Removal (Annexin
V) Kit (StemCell Technologies) following the manufac-
turer’s protocol. This was not performed for tumours that
had too low of a total cell yield (less than 1 × 105 cells) fol-
lowing dissociation and splitting across cryopreservation
conditions. Enriched cell suspensions were resuspended in
a final solution of PBS with 10% FBS solution prior to load-
ing on the 10X Chromium platform.
For the processing of cryopreserved replicates, samples
were frozen at −80 °C for ~ 1 week followed by ~ 5 weeks
at −196 °C for prior to scRNA-Seq. For obvious logistical
reasons (freezing storage time), FT samples were run on
the 10X Chromium platform immediately whilst CT and
CSS samples were processed simultaneously at a later
date. Following cryopreservation, samples were thawed
in a 37 °C water bath and washed multiple times with
RPMI 1640. CT samples were dissociated in the same
manner as the FT samples, as described above. In gen-
eral, we observed a lower cell viability in cryopreserved
samples compared to their respective FT sample, as
measured using Trypan Blue. Cryopreserved samples
were enriched for live cells if viability was assessed to be
< 80%, as described above. Viability enrichment was not
performed or repeated multiple times for samples that
had less than 1 × 105 cells. For both cryopreserved repli-
cates from breast tumours, the mouse cell line NIH3T3
was thawed and spiked in at 2% of the total cell number
prior to cell loading on the 10X Chromium. The CCS
sample for PC-P2 resulted in a very low cell number
(less than 400) after sequencing and was excluded from
subsequent cluster and cell annotation analyses. This
sample had a very low emulsion volume and was due to
an instrumental failure on the Chromium 10X platform,
likely due to a microfluidic clogging issue.
Single-cell RNA sequencing on the 10X chromium
platform
High throughput scRNA-Seq was performed using the
Chromium Single Cell 3′ v2 and 5′ chemistry (10X Gen-
omics) according the to the manufacturer’s instructions.
All replicates within a case were captured using the
same chemistry. A total of 6000 cells were targeted per
lane. The scRNA-Seq libraries were sequenced on the
Illumina NextSeq 500 platform with pair-end sequencing
and dual indexing according to the recommended Chro-
mium platform protocol; 26 cycles for Read 1, 8 cycles
for i7 index and 98 cycles for Read 2.
Data processing
Read demultiplexing and alignment to the GRCh38
human reference genome was performed using the Cell
Ranger Single Cell Software v2.0 (10X Genomics) with
the cellranger mkfastq and count functions, respectively.
For cryopreserved replicates from breast tumours with
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mouse cell line spike in (NIH3T3), the above steps were
performed using the GRCh38 human and mm10 mouse
reference genomes. Raw count matrices were filtered for
‘real’ barcodes using the EmptyDrops package in R
which calculates deviations against a generated ambient
background RNA profile [16]. Additional conservative
cutoffs were further applied based on the number of
genes detected per cell (greater than 200) and the
percentage of mitochondrial unique molecular identifier
(UMI) counts (less than 20%). Filtered barcodes from
matched replicates were then processed and integrated
using the Seurat v3 package in R as per the developers’
vignettes [17]. For the comparison of transcript metrics
across cryopreserved replicates, including the number of
genes, UMIs and gene correlations, we performed down-
sampling of sequencing libraries by the total number of
mapped reads using the cellranger aggr function. For
comparison of clusters across cryopreservation condi-
tions, cells were randomly downsampled to the lowest
replicate size using the data.table package in R.
Silhouette scores, mixing metric and local structure
metric
We applied clustering and mixability metrics from Stuart
et al. to quantitative measure the robustness of the cryo-
preserved replicates to reflect good technical replicates
with the FT [17]. Stratified random downsampling was
first applied to each case to generate clusters with equal
sizes across all three conditions. This was performed
using data.table package in R. As a positive control, FT
datasets were randomly downsampled to generate two
pseudo-replicates. Three comparisons were computed
per case: FT-1 vs FT-2, FT-1 vs CCS and FT-1 vs CT.
For the melanoma case, the comparisons were FT-1 vs
FT-2, FT-1 vs CCS and FT-1 vs CO. Silhouette scores,
mixing metrics and local structure metrics were all com-
puted using code adopted from the Seurat v3 package [17].
Bulk and cluster level gene correlations
Adjusted R2 correlation values were calculated using
linear regression, implemented in R. Sequencing libraries
normalised by the number of mapped reads using Cell-
Ranger were used. Pseudo-replicate bulks and cluster-
level bulks were generated from log-normalised gene
expression values. FT bulk and cluster level replicates
were compared to cryopreserved replicates (CCS/CT/CO).
Differential gene expression and pathway enrichment
Integrated cases were split by replicate. Differential gene
expression was then performed between integrated clus-
ter IDs across each of the replicates using the MAST
method through the FindAllMarkers function in Seurat
(log fold change threshold of 0.25, p value threshold of
1 × 10− 5 and FDR threshold of 0.05) [18]. All DEGs from
each cluster were then passed on to the ClusterProfiler
package for functional enrichment [19]. The compar-
eCluster function was used with the enrichGO default
CC sub-ontology under the human org.Hs.eg.db data-
base. The overlaps of detected GO pathways across each
replicate were computed and visualised using the euler
and ggplot2 packages in R. The same parameters de-
scribed above were used for differential gene expression
and GO pathway comparisons between conditions
across all cells and cluster/cell type level.
CITE-Seq staining and data processing
Samples were stained with 10X Chromium 3′ mRNA
capture compatible TotalSeq-A antibodies (BioLegend,
USA). Staining was performed as previously described
by Stoeckius et al. (2017) with a few modifications [9].
Briefly, a maximum of 2 million cells per sample was
resuspended in 100 μl of cell staining buffer (BioLegend,
USA) with 5 μl of Fc receptor Block (TrueStain FcX,
BioLegend, USA) for 15 min followed by a 30 min stain-
ing of the antibodies at 4 °C. A concentration of 1 μg/
100 μl was used for all antibody markers used in this
study. The cells were then washed 3x with PBS contain-
ing 10% FBS media followed by centrifugation (300xg for
5 min at 4 °C) and expungement of supernatant. The
sample was then resuspended in PBS with 10% FBS for
10X Chromium capture. Indexed CITESeq libraries were
spiked in to 10X scRNA-Seq libraries for sequencing on
the NextSeq500 platform (Illumina). Reads were demul-
tiplexed using CellRanger v2.0. Cell counts of CITE anti-
bodies were calculated from sequenced CITE libraries
with CITE-seq-Count v.1.4.3 using default parameters
recommended by developers. Counts were integrated
with scRNA-seq data using Seurat (v.3.1.4), scaled and
normalised.
Results
Cryopreservation allows for robust conservation of
cellular heterogeneity in human breast cancers
The preservation of cellular heterogeneity is an import-
ant factor for analysing solid cancers. We first investi-
gated this in primary human breast cancers collected
from three patients. To minimise spatial biases from
regional sampling, fresh surgical specimens were initially
cut in to 1–2 mm3 pieces and thoroughly mixed. One
third of the mix was immediately cryopreserved with
DMSO at −80 °C (designated as the cryopreserved tis-
sue—CT), and the remaining mix was dissociated into a
single-cell suspension using a commercial kit-based
method (see the “Methods” section). A fraction of this
cell suspension was immediately cryopreserved with
DMSO at −80 °C (designated as the cryopreserved cell
suspension—CCS), and the remaining of this cell suspen-
sion was processed immediately for scRNA-Seq using the
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Chromium 10X platform (designated as fresh tissue—FT).
After storage of the cryopreserved samples, both CT and
CCS, at −80 °C for about 1 week, they were stored in
liquid nitrogen at −196 °C for up to 5 weeks to mimic
standard tissue biobanking procedures. Following cryo-
preservation, CT and CCS samples were thawed and
processed for scRNA-Seq in the same manner as the FT
sample. For cryopreserved replicates, we spiked in the
mouse NIH3T3 fibroblast cell line as a positive con-
trol (~ 2%) for the scRNA-Seq experimental workflow.
In total, we sequenced 23,805, 29,865 and 24,250 cells
from breast cancer patients 1–3, (assigned as BC-P1,
BC-P2 and BC-P3), respectively.
A detailed comparison was performed between sam-
ples processed as FT, CCS or CT (Fig. 1a). We per-
formed batch correction and integration of all
matched fresh and cryopreserved replicates using the
anchoring based method in Seurat v3 (Fig. 1b) [17].
This revealed consistent ‘mixability’ across the three
conditions, where a strong overlap was also observed
in Uniform Manifold Approximation and Projection
(UMAP) space. This was also observed in the non-batch
corrected data (Additional file 2: Figure S1a), reflecting
good technical replicates on the 10X Chromium platform.
To account for variation in cell-type proportions, all
matched conditions were downsampled to the lowest rep-
licate cell number to examine the composition of cells in
each cluster (Fig. 1c). Only three clusters across all three
datasets were not comprised of cells from all three condi-
tions (Fig. 1c). These differential clusters were all detected
in the BC-P2 dataset, including clusters c11 (737 cells),
c18 (191 cells) and c23 (27 cells). Clusters c11 and c18
were only detected in the FT sample and resembled cell
doublets captured from a varying number of cells se-
quenced per replicate, which ultimately contributes to dif-
ferences in the expected doublet rate. These clusters
showed characteristics of cell doublets, including the ex-
pression of markers from multiple cell lineages such as
EPCAM, PTPRC, PECAM1 and PDGFRB (Additional file
2: Figure S1b). Cluster c23 was comprised of smaller cell
numbers, and may be a result of sampling rarer cell types,
rather than from the cryopreservation process. To our
surprise, the mouse NIH3T3 fibroblast spike-ins could
also be detected in all cryopreserved replicates following
the mapping of reads to the human GRCh38 reference
genome alone (c19 in BC-P1, c17 in BC-P2 and c14 in
BC-P3). These were confirmed as mouse cells by re-
mapping reads to both human and mouse reference ge-
nomes, suggesting that mouse reads were assigned to their
human orthologs when mapping to a single reference gen-
ome using CellRanger. NIH3T3 fibroblast spike-ins cap-
tured from different cryopreserved replicates and
independent experiments mixed well (Additional file 2:
Figure S1c), indicating high reproducibility on the 10X
Genomics platform. As expected, NIH3T3 fibroblasts
highly expressed markers Dlk1, Acta2, Vim, Actg1, Col1a1
and Col1a2 (Additional file 2: Figure S1d).
From investigating the expression of canonical cell
type markers, we identified a strong preservation of
major cell lineages in cryopreserved replicates (Fig. 1d).
As observed in the representative case BC-P1 (Fig. 1d),
we identified a strong conservation of the housekeeping
gene ACTB, cancer/epithelial cells (EPCAM; clusters c1,
c5, c13, c20 and c14), myoepithelial cells (KRT14; c6), T
cells (CD3D; c3, c7 and c17), B-cells (MS4A1; c16),
plasmablasts (JCHAIN; c18), myeloid cells (CD68; c12
and c21), endothelial (PECAM1; c0, c8, c9, c11, c15 and
c22), perivascular cells (PDGFRB; c2) and cancer-associated
fibroblasts (CAFs; PDGFRA; c4 and c10) (Fig. 1b, d;
Additional file 2: Figure S2a; Additional file 3). Similar
trends in the preservation of the TME were observed in all
three breast cancer cases (Additional file 2: Figure S1b;
Additional file 2: Figure S2b-c; Additional file 3). Consistent
with the even distribution of cells from each condition
across all the breast tumour clusters (Fig. 1c), these cluster
annotations were also detected when analysing each
sample individually using unbiased clustering and
UMAP (Additional file 2: Figure S3a-c). In summary,
cryopreservation of human breast cancers as either
solid tissue or single cell suspension maintains the
heterogeneity of major cell lineages detected from
processing fresh tissue.
Cryopreserved replicates resemble good technical
replicates with the fresh tissue data
Although visual inspection of the dimensional reduction
UMAP plots indicated good mixability and minimal
technical variation emerging from cryopreservation, we
applied several metrics adopted from Stuart et al. [17] to
quantitatively measure the impact on downstream clus-
tering. We examined silhouette coefficient scores, mix-
ing metric and local structure metric to measure the
robustness of cryopreservation to reflect good technical
replicates with the FT. As described in the previous sec-
tion, we performed stratified downsampling of cells to
account for differences emerging from the total number
of cells sequenced. We compared cells from FT against
cells from matched cryopreserved replicates independ-
ently in the following comparison conditions: FT vs CCS
and FT vs CT. As a positive control, we compared two
sets of FT cells downsampled from the same dataset to
reflect perfect technical replicates (FT-1 vs FT-2).
Silhouette coefficient scores, which range from − 1 to
+ 1, measure how similar a cell is to cells from its own
cluster in dimensional reduction space. We applied this
to measure the mixability of the cryopreserved replicates,
where scores closer to 0 indicate a higher mixability be-
tween replicates irrespective of cryopreservation
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Fig. 1 (See legend on next page.)
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condition. As expected from our positive control compari-
sons (FT-1 vs FT-2), this yielded average silhouette scores
close to 0 for all three breast cancer cases (Fig. 1e). In gen-
eral, we observed values close to 0 for all cryopreserved
replicate comparisons, with no silhouette scores outside of
the −0.25 to 0.25 range (Fig. 1e). Minor variations, as
indicated through increased standard deviations, were ob-
served in the CCS replicates of two cases: BC-P1 and BC-
P3 (Fig. 1e; Additional file 4). Similarly, increased standard
deviations were observed when comparing CT replicates
in two cases: BC-P1 and BC-P2 (Fig. 1e; Additional file 4).
We next applied the mixing metric to assess how well
cryopreserved replicates ‘mixed’ with the FT data after
integration (Fig. 1f). The mixing metric examines the
distribution of replicates in a cell’s neighbourhood (k = 5
and k.max = 300), where values closer to 300 resemble a
high ‘mixability’ [17] (Fig. 1f). Overall, very high mixing
metric scores were observed across the comparison
conditions from all three breast cancer cases; however,
slightly lower values and higher standard deviations were
consistently detected in cells cryopreserved as CT
compared to CCS (Fig. 1f; Additional file 4). Finally, we
assessed how local cell clusters (k = 100) detected in in-
dividual replicates were preserved upon data integration
using the local structure metric [17]. In all three cases,
this revealed no significant differences in the standard
deviations from our positive FT control comparisons
and the cryopreserved replicates (Fig. 1g; Additional file
4), indicating that the clusters identified in individual
replicates were largely consistent upon integration with
the FT data. Overall, we conclude that cryopreservation
can yield good quality technical replicates. Only minor
variations in clustering, as determined by silhouette co-
efficients and mixing metrics, arose from processing as
dissociated CCS and solid CT, with the latter resulting
in slightly more variable data.
Cryopreservation yields high-quality data in prostate
cancers and a metastatic melanoma
Tissue architectures differ across cancer sites and meta-
static lesions. To assess the impact of cryopreservation
across different tissue sites, we repeated our benchmark-
ing on primary prostate cancer tissue collected from two
patients (PC-P1 and PC-P2), and a regional lymph node
metastasis collected from one patient with a known
cutaneous melanoma (M-P1). For the metastatic melan-
oma sample, we benchmarked cell suspensions cryopre-
served immediately (CCS sample) as well as after
overnight cold storage of the tissue at 4 °C in media
(designated as cryopreserved overnight—CO). The CO
replicate mimics conventional biobanking procedures
where tissue is collected from late patient procedures,
stored at 4 °C and processed the following day. In total,
we sequenced 18,333, 18,327 and 21,363 cells from PC-
P1, PC-P2 and M-P1, respectively (Fig. 2a). Here, the
CCS replicate from PC-P2 resulted in low cell number
and was excluded from subsequent comparisons (see the
“Methods” section). Similar to the breast cancer data,
comparisons of the non-batch corrected data revealed a
good mixture of cells from all conditions, reflecting that
of good technical replicates (Additional file 2: Figure
S1a). Batch correction and data integration revealed con-
sistent mixability across the three conditions in UMAP
space (Fig. 2a, b; Additional file 2: Figure S1e). Only one
very small cluster in PC-P1 (c2 - 64 cells) was not
comprised of cells from all three conditions (Fig. 2c) and
is again likely a result of cell sampling rather than
cryopreservation. All clusters detected in M-P1 were
comprised of cells from all conditions (Fig. 2c). Similar
to our benchmarking in breast cancers, we observed a
strong conservation of the housekeeping gene ACTB
and markers for cancer clusters (EPCAM in prostate and
MITF in melanoma), immune subsets (PTPRC), endo-
thelial cells (PECAM1/CD31) and fibroblast/perivascular
(PDGFRB) cells in prostate cancers and the metastatic
melanoma (Fig. 2d, e; Additional file 2: Figure S1f;
Additional file 2: Figure S2d-f). These cluster annota-
tions could also be detected when analysing each condi-
tion individually using unbiased clustering and UMAP
(Additional file 2: Figure S3d-e). Upon examining clus-
tering metrics, we found similar trends with slightly
higher variation in silhouette scores and mixing metrics
(See figure on previous page.)
Fig. 1 Cryopreservation allows for robust cell-type detection in clinical breast cancer samples. a Experimental workflow. b UMAP visualisation of
23,803, 29,828 and 24,250 cells sequenced across dissociated fresh tissue (FT; green), dissociated cryopreserved cell suspensions (CCS; orange) and
solid cryopreserved tissue (CT; purple) replicates from three primary breast cancer cases (BC-P1, BC-P2 and BC-P3). UMAPs are coloured by
cryopreserved replicate (top) and by cluster ID (bottom) with cell types annotations overlayed. Matched replicates were integrated using the
Seurat v3 method. c Number of cells detected per cluster. Cells were downsampled to the lowest replicate size. d FeaturePlot visualisations of
gene expression from BC-P1 fresh and cryopreserved replicates, showing the conservation of the housekeeping gene ACTB and heterogeneous
cancer/epithelial (EPCAM), immune (PTPRC/CD45), endothelial (PECAM1/CD31) and fibroblast/perivascular (PDGFRB) clusters. e, g Distribution of
silhouette scores (range −1 to + 1) (e), mixing metric (f) and local structure metrics (g) of clustering following cryopreservation. Samples were
downsampled by replicate and cluster sizes and compared to the respective FT samples. Cell comparisons were performed across downsampled
FT-1 vs FT-2 cells (positive control), FT vs CCS cells and FT vs CT cells. Stars represent standard deviations: e silhouette scores s.d. 0.02–0.05* and
s.d. > 0.05**; f mixing metrics s.d. 2–10* and s.d. > 10**; g local structure metrics s.d. > 0.05*
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emerging from cells cryopreserved as CT compared to
CCS (Fig. 2f, g; Additional file 4). For the melanoma
comparisons, the CO replicate exhibited a much higher
variation in silhouette scores and mixing metric
compared to CCS, indicating potential transcriptional
artefacts arising from overnight cold preservation prior
to cryopreservation (Fig. 2f, g; Additional file 4). No
major differences were observed in the local structure
metric of both prostate and melanoma cases (Fig. 2h),
indicating that clustering neighbourhoods in individual
replicates were consistently detected upon integration




















































































































































Fig. 2 Cryopreservation allows for robust cell-type detection in clinical prostate cancer and melanoma samples. a UMAP visualisation of 18,331 cells
sequenced across FT (green), CCS (orange) and CT (purple) from primary prostate cancer case PC-P1. UMAPs are coloured by cryopreserved replicate (top)
and by cluster ID (bottom) with cell types annotations overlayed. Matched replicates were integrated using the Seurat v3 method. b UMAP visualisation as
in a of 21,361 cells sequenced across FT (green), CCS (orange) and cryopreserved overnight (CO; purple) replicates from metastatic melanoma case M-P1. c
Number of cells detected per cluster from PC-P1 and M-P1, highlighting the conservation of clusters detected in the FT samples following
cryopreservation. Cells were downsampled to the lowest replicate size. d, e FeaturePlot visualisations of gene expression in prostate cancer (d) and
melanoma (e) showing the conservation of the housekeeping gene ACTB and heterogeneous cancer/epithelial (EPCAM in d or MITF in e), immune (PTPRC/
CD45), endothelial (PECAM1/CD31) and fibroblast/perivascular (PDGFRB) clusters following cryopreservation as FT, CCS and CT or CO. f–h Distribution of
silhouette scores (f), mixing metric (g) and local structure metrics (h) of clustering following cryopreservation as analysed in Fig. 1e–g. Stars represent
standard deviations: f silhouette scores s.d. 0.02–0.05* and s.d. > 0.05**; gmixing metrics s.d. 2–10* and s.d. > 10**; h local structure metrics s.d. > 0.05*
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Impact of cryopreservation on cellular stress
As we observed small decreases in cell viability follow-
ing cryopreservation, we next examined the annotated
scRNA-Seq datasets from all tumour types to see if this
was a broad effect or rather impacted a specific cell
type. This did not reveal any significant trends for the
seven common cell types annotated across all tumours
analysed (B-cells, CAFs, cancer/epithelial, monocyte/
macrophage, plasmablasts, perivascular cells and T-
cells), suggesting there are no cell-type specific impacts
following cryopreservation (p > 0.05, paired t test; data
not shown). We next assessed the percentage of mito-
chondrial transcripts per cell, which is a commonly
assessed metric in scRNA-Seq data to determine cell
viability [20]. Cells undergoing stress have higher per-
centages of mitochondrial transcripts from either per-
meable membranes, causing loss of cytoplasmic mRNA,
genome degradation or increased metabolic demand
[20]. In the general comparisons of all cells, two of five
samples analysed as CCS (BC-P3 and M-P1) and two of
five samples analysed as CT (PC-P1 and PC-P2) had
significantly higher mitochondrial percentages com-
pared to FT (Additional file 2: Figure S4a). These differ-
ences were dispersed across multiple cell types in each
respective sample (Additional file 2: Figure S4b-f),
where cancer/epithelial cells were the only consistent
cell type to have significantly increased mitochondrial
percentages across more than one case (CCS condition
from BC-P2, BC-P3 and M-P1). Despite these minor
differences, all cell types sequenced across all condi-
tions and tumours had a mean mitochondrial percent-
age of less than 10% (Additional file 2: Figure S4b-f),
suggesting that the survival and viability of specific cell
types were not markedly impacted by cryopreservation.
Taken together, our benchmarking across multiple tis-
sue sites indicates that cryopreservation preserves the
cellular heterogeneity of the TME and acts as good
quality technical replicates.
Tumour cryopreservation maintains the integrity and
complexity of single-cell transcriptomes
We next investigated whether gene expression and
transcriptome integrity were affected through the
cryopreservation process. We first examined the num-
ber of genes and unique molecular identifiers (UMIs)
detected per cell across cryopreserved replicates. For
this comparison, libraries were first downsampled by
the number of mapped sequencing reads to account
for differences emerging from varying sequencing
depths. This revealed that an average of 1809, 1842
and 1694 genes and 6149, 6525 and 5851 UMIs per
cell were detected across all FT, CCS and CT repli-
cates, respectively (Fig. 3a, b). Within matched cases,
only cryopreserved cell suspension conditions from
M-P1 (from both CCS and CO) yielded a lower aver-
age number of genes and UMIs per cell compared to
the FT (Fig. 3a, b). Similarly, only one CT replicate
(BC-P1) had a significantly lower number of genes and
UMIs detected per cell compared to the FT (Fig. 3a,
b). Although this was not observed across multiple
cases, a lower detection rate from CT may reflect a
minor impact on transcript abundance and quality
from the cryopreservation process. In addition, cell
type and cell size can be an important factor deter-
mining transcript abundance. To determine that these
subtle changes were not due to differences in cell
abundance across cryopreserved replicates, we con-
firmed that these changes were also present at the
cluster level (Additional file 2: Figure S5a-f). For ex-
ample, although cancer cells (clusters c1, c5 and c14
in BC-P1) generally hold more transcripts compared
to T cells (clusters c3, c7 and c17 in BC-P1), less genes
and UMIs were also found in these respective cell
types captured in CT replicate, as per the bulk com-
parisons (Additional file 2: Figure S5a).
We next investigated the gene correlation between
FT samples and their respective cryopreserved repli-
cates. Bulk gene correlations revealed high R2 values
between FT and all cryopreserved replicates (R2 > 0.90;
Fig. 3c) where on average, CCS replicates had higher
R2 values with the FT sample (mean R2 = 0.98, min =
0.95 and max = 0.99) compared to the CT replicates
(mean R2 = 0.96, min = 0.93 and max = 0.99) (Fig. 3c).
Similarly, we examined if this trend was unique to
particular cell types on the cluster level (Fig. 3d). Only
clusters containing cells from all three replicates with
a minimum cluster size 100 and at least 20 cells per
replicate were examined for representative gene corre-
lations, in order to not be skewed by low cell numbers.
Cluster correlations revealed consistent trends with
the bulk comparisons, where CCS replicates consist-
ently showed slightly higher R2 correlation than with
FT replicates (Fig. 3d). Although a majority of clusters
displayed high correlations (R2 > 0.90; indicated by the
red line in Fig. 3d), several smaller clusters showed sig-
nificantly lower correlations than the bulk (R2 < 0.90;
Fig. 3d) including five clusters in BC-P1 (c13—cancer/
epithelial, c20—cancer/epithelial, c17—T cells, c11—
endothelial and c18—plasmablasts), four clusters in
BC-P2 (c19—perivascular, c21—pDCs, c20—T cells
and c22—plasmablasts), two clusters in BC-P3 (c7—
monocyte/macrophage and c17—unassigned cluster),
six clusters in PC-P1 (c17—NK cells, c5—cancer/epi-
thelial, c15—endothelial, c9 perivascular, c19—mast
cells and c14—cancer/epithelial) and one cluster in M-
P1 (c17—CAFs). The majority of these poorly corre-
lated clusters were comprised of small cell numbers.
The only cell type consistently found to have very poor
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correlation values across multiple cases (R2 < 0.80) was
plasmablasts (c18 in BC-P1 and c22 in BC-P2), sug-
gesting that this cell type is more prone to transcrip-
tional changes due to cryopreservation (Fig. 3d). Taken
together, we find that cryopreservation can conserve
high-quality transcriptomes for scRNA-Seq. These data
suggest that processing scRNA-Seq from CCS yields
slightly higher quality data than from CT. Although
the sample number was small, we found that cryopreser-
vation induced changes in transcriptome integrity of
plasmablasts identified in breast tumours, warranting
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Fig. 3 Cryopreservation maintains the integrity and complexity of single-cell transcriptomes in clinical human cancers. a, b Number of genes (a)
and UMIs (b) detected per cell across all FT, CCS, CT and CO replicates from breast (BC-P1, BC-P2 and BC-P3), prostate (PC-P1 and PC-P2) and
melanoma samples (M-P1). Sequencing libraries were downsampled to equal number of mapped reads per cell using the cellranger aggregate
function to account for differences in sequencing depth. Note that only one CCS replicate in M-P1 (orange) and one CT replicate in BC-P1
(purple) had significantly lower number of genes and UMIs per cell compared to their matching FT replicate. Statistical significance was
determined using an unpaired Student’s t test. P values denoted by asterisks: *p < 0.05, p < 0.01, *p < 0.001 and ****p < 0.0001. c Pseudobulk
gene correlations between FT cells with CCS (red line) and CT or CO (blue line) replicates. Correlation values (adjusted-R2) were computed using
linear regression in R to model the log-normalised gene expression values between two replicates. In all cases, CCS replicates had higher R2
values compared to CT and CO comparisons. d Cluster-level gene correlations between FT cells with CCS (circle), CT (triangle) and CO (square)
replicates show similar trends with pseudobulk gene correlations. Dotted lines join corresponding clusters between different comparison
methods. Plasmablasts (c18 in BC-P1 and c22 in BC-P2) were the only cell type identified in multiple cases to have significantly lower correlations
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Tumour cryopreservation maintains biological pathways
detected in fresh tissue samples
Biological and functional findings from scRNA-Seq
experiments are often interpreted through gene ontology
(GO) analysis for pathway enrichments across unique cell
clusters. To assess if such downstream analyses are im-
pacted by cryopreservation, we first separated our inte-
grated clusters by their cryopreservation conditions. We
then performed differential gene expression and GO path-
way enrichment to assess how pathways detected across FT
clusters were detected in their respective cryopreserved
replicates. This analysis revealed a good overlap of total
detected pathways in all cancer cases, with over 64% of all
FT pathways consistently detected in both cryopreserved
replicates in all cases (min = 64% and max = 77%; Fig. 4a).
For pathways that were unique to FT replicates and not de-
tected in the matching cryopreserved replicates, no com-
mon pathways were shared across the FT replicates from
all six cases; however, a total of seven pathways were shared
across three cases. Though this may reflect gene expression
programs that might be affected by the cryopreservation
process, these pathways were mostly detected across differ-
ent cell types, with the exception of the gene sets GO:
0016628 (‘oxidoreductase activity’) and GO:0016791 (‘phos-
phatase activity’), which were unique to cancer/epithelial
cells and T-cells from three FT replicates, respectively
(Additional file 4). From the high concordance of GO path-
ways detected in cryopreserved replicates, we concluded
that these minor differences were likely due to the varia-
tions in the scRNA-Seq platform or false discovery rather
than the cryopreservation process.
We next assessed the variability of pathway enrich-
ment scores for cryopreserved cells from each cluster
(Fig. 4b–d). This analysis revealed minimal variability
across clusters from all six cases of breast cancers, pros-
tate cancers and melanoma, represented by the small
range of -log10 q value enrichment scores for cells
across FT and cryopreserved replicates (Fig. 4b–d;
Additional file 2: Figure S6a-c). Taken together, these
data indicate that the minor variations emerging from
cryopreservation, as shown previously through clustering




























































































































































































































































































Fig. 4 Methods of human tumour cryopreservation maintain biological pathways. a Euler diagrams highlighting the overlaps between gene ontology
(GO) pathways detected in FT clusters and cryopreserved replicates from CCS, CT and CO. A total of 315, 347, 368, 262, 230 and 311 pathways were
assessed from the FT replicates across the BC-P1, BC-P2, BC-P3, PC-P1, PC-P2 and M-P1 cases, respectively. b–d Sensitivity of pathway enrichment
scores detected in clusters across cryopreserved replicates of BC-P1 (b), PC-P1 (c) and M-P1 (d). The minimum, mean and maximum -log10 q value are
plotted in the error bars of each GO pathway. All DEGs from each cluster were passed on to the ClusterProfiler package for functional enrichment with
the CC sub-ontology under the human org. Hs.eg.db database. GO pathway descriptions can be found in Additional file 4
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3a, b) and gene correlations (Fig. 3c, d), only have minor
impacts on the conservation of key biological pathways.
Gene expression artefacts arising from tumour
cryopreservation
While the previous analysis examined the conservation
of biological pathways, we next examined if distinct
transcriptional artefacts emerged from the cryopreserva-
tion process i.e. pathways that were enriched in cryopre-
served conditions compared to their respective FT
sample. We first examined this on the bulk level com-
paring all cells in FT vs all cells in either the CCS or CT
samples using differential gene expression (Additional
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Fig. 5 Gene expression artefacts arising from cryopreservation. a–c Enrichment scores for gene ontology pathways that are unique to
cryopreservation conditions: cryopreserved cell suspension (CCS; a), cryopreserved tissue (CT; b) and cryopreserved after overnight cold storage
(CO; c). Comparisons were performed between all cells from each matched condition, which were first downsampled by total cell number and
total number of sequencing reads. For the CCS (a) and CT (b) conditions, only pathways that were shared across multiple cases were analysed,
which led to a total of 5 and 21 pathways for each condition, respectively. A total of 54 pathways were enriched in the CO (c) condition. Only
the top 10 pathways based on enrichment scores are plotted for CT (b) and CO (c) conditions. DEGs from each condition (Additional file 5) were
passed on to the ClusterProfiler package for functional enrichment with the CC sub-ontology under the human org.Hs.eg.db database. GO
pathway descriptions can be found in Additional file 6. d–h Expression violin plots of the genes HSPA1A, HSPA1B and HSP90AA1 from cell stress
response pathways (heat shock protein binding GO:0031072 and unfolded protein binding GO:0051082) that were commonly enriched across CT
and CO conditions. Tumours for BC-P1 (d), BC-P2 (e), BC-P3 (f), PC-P1 (g) and M-P1 (h) are grouped by their cryopreservation conditions: fresh
tissue (FT), CCS, CT or CO. Asterisk indicates significance values where adjusted p values are less than 0.05, as calculated using the MAST method
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focused on pathways that were detected in the same
condition across two or more tumours. This revealed a
total of 23 pathways that were unique to cells cryopre-
served as either CCS or CT. Five pathways were
enriched in cells cryopreserved as CCS (Fig. 5a), which
were related to chemokine receptor activity, cytokine ac-
tivity and ribosomal constituents however, these gene
sets and enrichment scores were relatively small, consist-
ing of 2–4 genes (Additional file 6). A total of 21 path-
ways were enriched in cells cryopreserved as CT (Fig.
5b), which included ribosomal constituents, transcrip-
tional/RNA polymerase activity, cellular stress response
(heat shock protein binding and unfolded protein bind-
ing) and ubiquitin ligase binding (Fig. 5b; Additional file
6). These pathways were not identified across all tu-
mours analysed as CT and were mostly detected in two
of the four tumours (Fig. 5b). For the melanoma sample
(M-P1) that was uniquely dissociated and cryopreserved
after overnight cold storage (CO), we identified a total of
54 pathways that were enriched in comparison to the FT
and CCS (Fig. 5c). This revealed an enrichment of path-
ways related to peptide and antigen binding (MHC), cel-
lular stress response (heat shock protein binding and
unfolded protein binding) and transcriptional activity/
RNA polymerase activity (Fig. 5c; Additional file 6).
We noticed that cellular stress response pathways such
as heat shock protein binding (GO:0031072) and un-
folded protein binding (GO:0051082) were commonly
enriched across CT and CO conditions, which included
several heat-shock related genes including HSPA1A,
HSPA1B and HSP90AA1 (Additional file 6). Previous
studies have reported similar transcriptional artefacts
emerging from cryopreservation in the analysis of
immune cells from PBMCs [15]. While these genes were
upregulated in CT and CO conditions, they were
generally robustly expressed across every condition and
tumour analysed (Fig. 5d–h). As these heat shock-
related pathways (Fig. 5b) and genes (Fig. 5d–g) were
modestly upregulated in the CT condition of breast and
prostate tumours, it suggests that cells which are first
cryopreserved as solid tissue (CT) may undergo an
added stress response during cryopreservation or when
thawed and dissociated [20, 21] compared to cells proc-
essed immediately. It is worth noting that these differ-
ences were relatively minor and not detected across
every tumour analysed. In contrast, we found a much
stronger enrichment of these stress pathways (Fig. 5c)
and genes (Fig. 5h) in the CO condition of the M-P1
tumour, suggesting that overnight cold storage of
tumour tissue prior to lab processing results in more
transcriptional artefacts related to cell stress responses.
When we repeated this analysis on the cluster and cell
type level, we found that most of these impacted path-
ways, including cell stress responses and heat shock,
were well distributed across all cell types, suggesting that
these transcriptional artefacts were not unique to a spe-
cific cell type (Additional file 2: Figure S6d-f; Additional
file 7; Additional file 8). However, we did notice that the
total number of pathways unique to cryopreserved cells
were skewed towards cancer/epithelial cells, T cells and
monocytes/macrophages, which had a total of 44, 14 and
8 pathways shared across the same condition in multiple
cases (Additional file 2: Figure S6e-f; Additional file 8).
Other cell types that had pathways shared across mul-
tiple cases were endothelial cells (5) and B cells (2),
while no shared pathways for CAFs and perivascular
cells were found (Additional file 2: Figure S6e-f;
Additional file 8). Our previous analysis with batch
correction (Fig. 1b–g, Fig. 2a–h) and without batch cor-
rection (Additional file 2: Figure S1a) found no unique
clustering by cryopreservation condition, suggesting that
these minor transcriptional changes have no substantial
impact on the overall gene expression profile of cryopre-
served cells; however, it does warrant caution when
interpreting these specific stress response pathways in
downstream analyses. Taken overall, cells cryopreserved
as CT or CO may undergo an added stress response
from cryopreservation or when thawed and dissociated.
Consistent with our earlier findings, these conditions
result in slightly more variable data compared to cells
cryopreserved as suspensions immediately (CCS).
Whole cell cryopreservation allows for highly robust
immunophenotyping using CITE-Seq
Immunophenotyping with barcoded-antibody methods
such as CITE-Seq can be powerfully applied to simultan-
eously integrate protein and gene expression in single
cells. Although previous studies have applied CITE-Seq
to cryopreserved PBMCs, it is yet to be established
whether CITE-Seq can be applied to cells cryopreserved
as solid tissues [9]. As cell surface markers have been ex-
tensively used to characterise immune subpopulations,
such additional layers of phenotypic information can be
used to profile the tumour immune response in cryopre-
served patient samples. Here, we performed CITE-Seq
on a single breast cancer case cryopreserved as CT
(Fig. 6a) using a panel of 15 canonical cell type markers.
We first used a combination of canonical markers from
RNA expression to broadly annotate clusters (Fig. 6a;
Additional file 2: Figure S7a). From CITE-Seq, we were
able to validate our cell type annotations by showing the
highly specific antibody-derived tag (ADT) expression
levels of canonical markers on corresponding cell types.
For example, ADT levels of EPCAM on cancer/epithelial
cells (c0, c4, c8, c14 and c15), CD31 (PECAM1) and
CD34 on endothelial cells (c7 and c9), CD146 (MCAM)
on perivascular cells (c11), CD90 (THY1) and CD34 on
CAFs (c13) and CD45 (PTPRC) on immune cells (c3, c5
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and c12) (Fig. 6b, c; Additional file 2: Figure S7a).
Within the immune compartments, CD3 specifically
marked T cells, while CD4 and CD8 were more specific-
ally expressed on the respective T cell subpopulations
(Fig. 6b; Additional file 2: Figure S7a). ADT levels of the
activation marker CD69 and tissue resident marker
CD103 were heterogeneously expressed on T cell sub-
populations (Fig. 6b). CD11c and CD11d were highly
specific to monocyte/macrophage cell clusters (Fig. 6b).
Major histocompatibility complexes, MHC-II and MHC-
I, were highly expressed by endothelial cells, whereas
MHC-II was also detected on monocyte/macrophage
clusters (Fig. 6b).
ADT levels, which overcome several technical limita-
tions from gene drop-out, have a greater sensitivity than
UMI counts by scRNA-Seq. The average correlation
between ADT levels and the corresponding gene expres-
sion for this panel of 15 markers was 0.215 (min R2 =
0.003 and max R2 = 0.639; Additional file 2: Figure S7b).
This ranged significantly for different markers, particu-
larly for lowly expressed immunoregulatory molecules
such as CD4 (CD4), CD103 (ITGAE), CD11b (ITGAM)
and CD11c (ITGAX), where expression levels of their
corresponding genes were lowly detected in comparison
to the ADT, with R2 values of 0.016, 0.005, 0.019 and
0.004, respectively (Additional file 2: Figure S7b). In
contrast, highly expressed genes such as the endothelial
cell marker CD31 (PECAM1) showed much higher
correlations (R2 = 0.639; Additional file 2: Figure S7b). In
summary, we show that good quality CITE-Seq data can
be generated from cells cryopreserved as solid CT. Such
methods can be used to powerfully extract additional
phenotypic information from low amounts of cryopre-
served clinical tissue, aiding the annotation of single-cell
clusters and the detection of clinically relevant molecules
such as immune-checkpoints.
Discussion
We show that high-quality scRNA-Seq data can be
generated from human cancer samples cryopreserved as
dissociated single-cell suspensions (CCS) and solid tis-













































































































































































































Fig. 6 Cryopreservation provides high quality immunophenotyping using CITE-Seq. a UMAP visualisation of 2621 cells sequenced from a breast
cancer case cryopreserved as CT. Clusters were annotated based on canonical cell type markers by RNA expression. CITE-Seq was performed on
this case using a panel of 15 canonical cell type markers. b Heatmap of rescaled antibody-derived tag (ADT) values for relevant markers for
cancer/epithelial cells (EPCAM), endothelial cells (CD31/PECAM1 and CD34), perivascular cells (MCAM/CD146 and THY-1/CD90), cancer-associated
fibroblasts (THY-1/CD90 and CD34), immune cells (CD45/PTPRC), T-cells (CD3, CD4, CD8, CD69 and CD103), monocytes/macrophages (CD11c and
CD11d) and MHC molecules (MHC-II and MHC-I). c FeaturePlot representation of ADT protein expression values for selected markers from b
highlighting the specificity of major lineage markers on RNA based clustering in a
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following sample collection and can be conducted rou-
tinely in hospital pathology laboratories that have access
to −80 °C freezers for short-term storage. These samples
can later be transported to research laboratories for long-
term storage or further processing. We did however find
that CCS samples yielded slightly higher quality data;
however, this requires more specialised tissue processing
following sample collection before cryopreservation (~ 1–
2 h using commercial dissociation kits). The minor de-
crease in the quality of tumours sequenced as CT is likely
due to a reduced efficiency of the cryoprotectant in solid
tissue fragments, with the small possibility that these cells
are more fragile and prone to transcriptional changes
during tissue dissociation. While we used tissues that had
been cryopreserved for up to 6 weeks in this study, we
have routinely processed samples stored at liquid nitro-
gen for more than 3 years for scRNA-Seq. Our similar
findings for the metastatic melanoma cryopreserved after
overnight cold storage warrants some caution for specific
heat-shock and stress response pathways in downstream
analyses using this method.
Most importantly, we show that the complexity of the
TME is conserved following cryopreservation as both CCS
and CT. This is an important consideration because an
integrated understanding of the neoplastic, stromal and im-
mune states defines tumours and their response to treat-
ment. A limitation of our study is the comparisons of
cancers that are mostly of the adenocarcinoma histopath-
ology; however, these cryopreservation methods are likely
applicable to other cancer types which may require slightly
modified sample preparation and dissociation protocols.
Further, we show that multi-omics methods, such as
immunophenotyping using CITE-Seq, can be performed
using cells cryopreserved as solid tissue pieces, which is im-
possible when using other preservation methods such as
single nuclei sequencing from snap frozen tissues. Our
CITE-Seq data is limited to a single breast cancer sample,
and future comparisons with data generated from add-
itional fresh tissues can be used to further assess the impact
of cryopreservation on CITE-Seq and the integrity of cell-
surface proteins. Lastly, our findings show that sample mul-
tiplexing methods can be applied to cryopreserved clinical
samples to reduce cost and logistics for project scaling, in-
cluding barcode hashing or genotype based demultiplexing
(unpublished data) [22, 23]. Such methods can also be used
to further minimise batch effects in larger patient cohorts,
allowing for more samples to be simultaneously thawed,
processed and sequenced in a single run.
Conclusions
We show that the viable cryopreservation of human can-
cers provides high-quality single-cells for multi-omics ana-
lysis. This can guide experimental designs for tissue
biobanking protocols for future clinical scRNA-Seq
studies. Due to the easily adoptable nature of cryopreserv-
ing solid tissues in tissue biobanking processes, we envis-
age our findings to positively impact the sample collection
opportunities for future clinical studies, particularly for
multi-site collaborative studies, to allow for the centralisa-
tion of sample processing and batched analysis.
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Cell Suspensions (CCS), Cryopreserved Tissue (CT) and Cryopreserved
Overnight (CO). b, Integrated cluster annotations. c, Cluster level
correlation values. Adjusted-R2 values computed using linear regression in
R to model log-normalised gene expression values between integrated
clustered cells from different cryopreserved replicates. d, Conservation of
cluster Gene Ontology (GO) pathways following cryopreservation. Func-
tional enrichment was first performed for all differentially expressed
genes in each integrated cluster in FT samples. Enrichment scores for
these pathways were then compared to the respective integrated cluster
in each cryopreserved replicate (CCS, CT, CO). All DEGs from each cluster
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CellRanger. The number of cells in each condition was randomly down
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Additional file 6. Gene pathways for all cells across cryopreservation
conditions. Shared Gene Ontology (GO) pathways for each
cryopreservation condition across the five tumours analysed. Only
pathways detected in the same condition in more than two tumours
were analysed. All DEGs from the comparison of all cells across
cryopreservation conditions (Additional file 5) were passed on to the
ClusterProfiler package for functional enrichment with the CC sub-
ontology under the human org.Hs.eg.db database.
Additional file 7. Differentially expressed genes for each cell type across
cryopreservation conditions. Differential gene expression was performed
using the MAST method within Seurat v3 with the RNA assay and default
parameters. Differential gene expression was performed using integrated
cluster data. Data from all conditions from each matched tumour dataset
were down sampled to the same number of mapped sequencing reads
using CellRanger. The number of cells in each condition was randomly
down sampled to match the condition with the lowest number of cells.
Additional file 8. Gene pathways for each cell type across
cryopreservation conditions. Shared Gene Ontology (GO) pathways for
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each cell type and cryopreservation condition across the five tumours
analysed. Only pathways detected in the same cell type and
cryopreservation condition in more than two tumours were analysed. All
DEGs from the comparison of annotated cell types across
cryopreservation conditions (Additional file 7) were passed on to the
ClusterProfiler package for functional enrichment with the CC sub-
ontology under the human org.Hs.eg.db database.
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